Sartorius Stedim, FR0013154002

Sartorius Stedim stock holds below EUR 190 ahead of Q3 results

Published on 09/18/2026 at 19:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sartorius Stedim stock recently closed at EUR 189.60 on Euronext Paris on September 9, 2026, about 4.2 percent below its 52-week high. The bioprocessing group plans to publish Q3 2026 results on October 22, 2026, giving investors a key next catalyst.

Fotorealistische Aufnahme einer sterilen Bioprozessanlage mit Einwegbeuteln und Bioreaktoren
Sartorius Stedim Biotech produziert sterile Einwegbeutel und Bioreaktoren für Biopharma-Hersteller weltweit, ISIN FR0013154002, Illustration mit AI erstellt.

Sartorius Stedim Biotech S.A. stock (ISIN FR0013154002) most recently closed at EUR 189.60 on Euronext Paris on September 9, 2026, leaving the shares roughly 4.2 percent below a level of EUR 198.60 reached earlier in September 2026.

Stock trades in mid-range of recent prices

According to MarketScreener, Sartorius Stedim shares traded at EUR 189.60 on September 9, 2026 on Euronext Paris, a daily decline of 0.42 percent from the prior close of EUR 190.40 on September 8, 2026.

In the same price history, the stock changed hands at EUR 198.60 on September 3, 2026, which means the September 9, 2026 closing level stood about 4.5 percent below that early September price point, illustrating that the shares have eased from their recent local high while remaining in the upper part of their short-term range.

Upcoming Q3 2026 earnings as main catalyst

As MarketScreener reports in its earnings calendar, Sartorius Stedim Biotech plans to publish its Q3 2026 results on October 22, 2026, setting a clear near-term date that many investors will mark as a potential turning point for the stock.

The same overview lists consensus revenue expectations for 2026 and 2027 in the billion-euro range, indicating that analysts continue to anticipate solid growth for the bioprocessing specialist, even though the precise forecast values are presented as aggregated estimates rather than final reported numbers.

Fundamental backdrop and investor focus

MarketScreener data for Sartorius Stedim Biotech summarize historical net profit figures in the hundreds of millions of euros for prior years, providing context that the company has previously converted a substantial portion of its bioprocessing revenue into bottom-line earnings, although these values relate to past reporting periods and therefore serve as historical comparison rather than current results.

With the upcoming Q3 2026 report scheduled for October 22, 2026, investors are likely to compare the new quarterly revenue and net profit against these earlier benchmarks to gauge whether Sartorius Stedim is reaccelerating after a period of share price consolidation evidenced by the move from EUR 198.60 on September 3, 2026 to EUR 189.60 on September 9, 2026.

Share price level for investors

Per the recent Euronext Paris data cited by MarketScreener, Sartorius Stedim Biotech stock closed at EUR 189.60 on September 9, 2026, with trading volume of 10,315 shares recorded that day, giving investors a reference price in the upper half of the early September 2026 trading range ahead of the Q3 2026 earnings release.

Sartorius Stedim Biotech stock key data

  • Company: Sartorius Stedim Biotech S.A.
  • ISIN: FR0013154002
  • Ticker: DIM
  • Trading venue: Euronext Paris
  • Price (as of September 9, 2026, 15:48): 189.60 EUR
  • Sector / Industry: Health Care / Biotechnology equipment
  • Index membership: Euronext indices

More news and analyses on Sartorius Stedim Biotech stock

Disclaimer...

en | FR0013154002 | SARTORIUS STEDIM | boerse | 70127115 | bgmi